Omega-3 Fatty Acid

New analyses from the REDUCE-IT study show icosapent ethyl significantly reduced total primary CV endpoints by 32% in patients with prior peripheral artery disease, suggesting substantial benefit for a high-risk population.

The use of vitamin D3 or omega-3 fatty acid supplements over a 5-year period may reduce the incidence of autoimmune disease in older adults by 25% to 30%, according to data presented at ACR Convergence 2021.

Recent data showed that omega-3 fatty acid supplements were linked to an increased risk for atrial fibrillation, and the risk increased with higher doses. A report on the data was the top story in cardiology last week.

Omega-3 fatty acid supplementation, especially at higher doses, was associated with elevated risk for atrial fibrillation, according to a meta-analysis of various large-scale randomized controlled trials published in Circulation.

In patients with prior MI from the REDUCE-IT cohort, icosapent ethyl reduced risk for first and total CV events compared with placebo, according to new data presented at the European Society of Cardiology Congress.

Healio and Cardiology Today have aggregated a list of the most-read news in cardiology of July 2021.

In the VITAL trial, marine omega-3 fatty acids did not prevent stroke, but they did reduce the risk for myocardial infarction compared with an olive oil placebo. A review of the data was the top story in cardiology last week.

Trials of omega-3 fatty acids have indicated they may have a role in CVD prevention, but the same cannot be said for vitamin D supplements, according to a speaker.

In a meta-analysis of omega-3 fatty acid trials, eicosapentaenoic acid monotherapy yielded the greatest reduction in CV risk vs. a combination of eicosapentaenoic acid and docosahexaenoic acid.

Healio and Cardiology Today have compiled a list of the top news from the virtual American College of Cardiology Scientific Session.